The company is focused on injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery. Here are five things to know about the funding.
1. The company closed a $14 million round of funding.
2. The Scandinavian Pension Fund led the funding with a new investment.
3. The funds will be used to grow global sales and marketing and accelerated expansion of the CERAMENT platform.
4. The CERAMENT is a synthetic bone substitute designed to remodel into bone within six to 12 months and was the first CE-marked injectable gentamicin antibiotic eluting bone graft substitute indicated to promote and protect healing in osteomyelitis management.
5. The CERAMENT is used in emerging prosthetic infections, diabetic foot ulcers, war injuries, high-energy trauma and sports injuries.
“We are uniquely positioned to address an unmet clinical need and this additional funding will help us quickly expand our product offerings and accelerate market penetration,” said BONESUPPORT CEO Lloyd Diamond.
More articles on orthopedic devices:
Ortho Kinematics raises $9.6M in Series C equity financing
NuVasive shares’ mean target price set at $54
Long Beach Memorial 1st in region to incorporate MAKOplasty procedures
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
